YU46503A - Farmaceutski oblik dronedarona za parenteralnu upotrebu - Google Patents

Farmaceutski oblik dronedarona za parenteralnu upotrebu

Info

Publication number
YU46503A
YU46503A YU46503A YUP46503A YU46503A YU 46503 A YU46503 A YU 46503A YU 46503 A YU46503 A YU 46503A YU P46503 A YUP46503 A YU P46503A YU 46503 A YU46503 A YU 46503A
Authority
YU
Yugoslavia
Prior art keywords
parenteral administration
pharmaceutical
composition
dronedarone
dronedarone composition
Prior art date
Application number
YU46503A
Other languages
English (en)
Inventor
Frederique Bourriague-Seve
Thierry Breul
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of YU46503A publication Critical patent/YU46503A/sh
Publication of RS50348B publication Critical patent/RS50348B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Predmet sadašnjeg pronalaska je farmaceutski oblik za parenteralnu primenu, naznačen time što uključuje: dronedaron ili neku od njegovih farmaceutski prihvatljivih soli kao aktivni princip; fiziološki prihvatljiv puferski rastvor sposoban da održi pH farmaceutskog oblika između 3 i 5; fiziološki prihvatljivi u vodi rastvorni ГЎ-cikodekstrinski derivat.[The invention concerns a pharmaceutical composition for parenteral administration, characterised in that it comprises: dronedarone or one of its pharmaceutically acceptable salts as active principle; a physiologically acceptable buffer solution capable of maintaining the pH of the composition between 3 and 5; a physiologically acceptable water-soluble ГЎ-cyclodextrin derivative.
YUP-465/03A 2000-12-11 2001-12-10 Farmaceutski oblik dronedarona za parenteralnu upotrebu RS50348B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0016071A FR2817750B1 (fr) 2000-12-11 2000-12-11 Composition pharmaceutique de dronedarone pour administration parenterale

Publications (2)

Publication Number Publication Date
YU46503A true YU46503A (sh) 2006-08-17
RS50348B RS50348B (sr) 2009-11-10

Family

ID=8857483

Country Status (31)

Country Link
US (1) US6939865B2 (sh)
EP (1) EP1343473B1 (sh)
JP (1) JP4399161B2 (sh)
KR (1) KR100849758B1 (sh)
CN (1) CN1235566C (sh)
AR (1) AR031649A1 (sh)
AT (1) ATE348599T1 (sh)
AU (2) AU1722902A (sh)
BG (1) BG66187B1 (sh)
BR (1) BR0116060B1 (sh)
CA (1) CA2427375C (sh)
CZ (1) CZ297788B6 (sh)
DE (1) DE60125411T2 (sh)
EA (1) EA005314B1 (sh)
FR (1) FR2817750B1 (sh)
HK (1) HK1055906A1 (sh)
HU (1) HU229372B1 (sh)
IL (2) IL155428A0 (sh)
IS (1) IS2349B (sh)
MA (1) MA26969A1 (sh)
ME (2) MEP20408A (sh)
MX (1) MXPA03005221A (sh)
NO (1) NO332294B1 (sh)
NZ (1) NZ525661A (sh)
OA (1) OA12416A (sh)
PL (1) PL199846B1 (sh)
RS (1) RS50348B (sh)
SK (1) SK287115B6 (sh)
TW (1) TWI246926B (sh)
WO (1) WO2002047660A1 (sh)
ZA (1) ZA200303406B (sh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1984028A2 (en) * 2006-02-14 2008-10-29 Wyeth a Corporation of the State of Delaware Aqueous pharmaceutical formulations of er selective ligands
GB0719180D0 (en) 2007-10-02 2007-11-14 Cambrex Karlskoga Ab New process
EP2280701A2 (en) * 2008-04-17 2011-02-09 Sanofi-Aventis Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
FR2959132A1 (fr) * 2010-04-22 2011-10-28 Sanofi Aventis Procedes pour l'evaluation et la reduction des risques
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
CN102342907A (zh) 2010-07-30 2012-02-08 江苏恒瑞医药股份有限公司 决奈达隆固体分散体及其制备方法
KR20120094557A (ko) * 2011-02-01 2012-08-27 동아제약주식회사 피에이치 비의존적 용출양상을 갖는 부정맥치료제 제제
CN102908307A (zh) * 2011-08-03 2013-02-06 天津市嵩锐医药科技有限公司 供注射用盐酸决奈达隆药物组合物及其制备方法
MX2015000532A (es) * 2012-07-12 2015-05-15 Sanofi Sa Composicion anti-tumoral que comprende el compuesto 1- (6- { [6- (4-fluorofenil) [1,2,4] triazolo [4,3-b] piridazin-3-il] sulfanil} -1,3-benzotiazol-2-il) -3- (2-morfolin-4-iletil) urea.
CN114377148B (zh) * 2020-10-20 2023-09-29 上海博志研新药物研究有限公司 盐酸决奈达隆药物组合物、其制备方法及应用
TW202320751A (zh) * 2021-08-16 2023-06-01 大陸商上海博志研新藥物技術有限公司 鹽酸決奈達隆注射組合物、其製備方法及應用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
JP2004327321A (ja) * 2003-04-25 2004-11-18 Jst Mfg Co Ltd コネクタ

Also Published As

Publication number Publication date
KR20030060985A (ko) 2003-07-16
SK7262003A3 (en) 2004-02-03
CN1235566C (zh) 2006-01-11
US20040044070A1 (en) 2004-03-04
IL155428A0 (en) 2003-11-23
IS2349B (is) 2008-04-15
MXPA03005221A (es) 2004-03-26
EP1343473B1 (fr) 2006-12-20
MEP20408A (en) 2010-06-10
NO20031958L (no) 2003-06-11
NO20031958D0 (no) 2003-04-29
NO332294B1 (no) 2012-08-20
CN1479610A (zh) 2004-03-03
MA26969A1 (fr) 2004-12-20
BR0116060A (pt) 2004-03-02
WO2002047660A1 (fr) 2002-06-20
CA2427375C (fr) 2011-02-01
US6939865B2 (en) 2005-09-06
ATE348599T1 (de) 2007-01-15
FR2817750B1 (fr) 2003-02-21
HK1055906A1 (en) 2004-01-30
KR100849758B1 (ko) 2008-07-31
DE60125411D1 (de) 2007-02-01
AU1722902A (en) 2002-06-24
CZ20031612A3 (cs) 2003-09-17
CZ297788B6 (cs) 2007-03-28
PL362788A1 (en) 2004-11-02
EP1343473A1 (fr) 2003-09-17
DE60125411T2 (de) 2007-10-11
AU2002217229B2 (en) 2006-05-18
PL199846B1 (pl) 2008-11-28
RS50348B (sr) 2009-11-10
TWI246926B (en) 2006-01-11
BG66187B1 (bg) 2011-12-30
NZ525661A (en) 2004-11-26
IL155428A (en) 2007-10-31
HUP0500842A2 (hu) 2005-12-28
ME00083B (me) 2010-10-10
JP4399161B2 (ja) 2010-01-13
JP2004528277A (ja) 2004-09-16
BR0116060B1 (pt) 2013-12-31
BG107748A (bg) 2004-03-31
SK287115B6 (sk) 2009-12-07
CA2427375A1 (fr) 2002-06-20
EA005314B1 (ru) 2004-12-30
EA200300406A1 (ru) 2003-10-30
IS6801A (is) 2003-04-30
ZA200303406B (en) 2004-05-03
HU229372B1 (en) 2013-11-28
FR2817750A1 (fr) 2002-06-14
AR031649A1 (es) 2003-09-24
OA12416A (fr) 2006-04-18

Similar Documents

Publication Publication Date Title
YU46503A (sh) Farmaceutski oblik dronedarona za parenteralnu upotrebu
ATE333265T1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
MY122124A (en) Solid pharmaceutical composition containing benzofurane derivatives
HUP0302086A2 (hu) Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
MX9710206A (es) Composicion farmaceutica de amiodarone para administracion parenteral.
IL165786A0 (en) Ibuprofen suspension
SI1121127T1 (en) Oral pharmaceutical compositions containing buprenorphin
IL141236A0 (en) New oral formulations for 5-ht4 agonists or antagonists
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
ES2197781A1 (es) Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
HK1045937A1 (en) Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
ECSP982396A (es) Composiciones que contienen tetrahidrolipstatina
CA2373166A1 (en) Antiulcer agent
MY120631A (en) Novel pharmaceutical combination having analgesic activity